Taken together, these results revealed that the conserved cancer-cell intrinsic CRC-enhancerome, shared by all PDOs and thus independent of patient-to-patient tumor molecular diversity, is largely under the regulatory control of YAP/TAZ, suggesting that these transcriptional activators serve as central players in the epigenetic deregulation of CRC. This evidence concerns the gene YAP1 and cancer.